GILD

Gilead Sciences
D

GILD

Arincen87/100B
166.870
USD
-0.73
(-0.44%)
Pre Open·168.040USD+1.170(+0.70%)
Last updated: · Delayed 15 min

Gilead Sciences EPS (earnings per share) 1990–2026

Gilead Sciences's diluted EPS in Q3 FY2026, the three months to 30 September 2026, was 1.94 USD, down 20.2% on the same quarter a year before. Gilead Sciences's diluted earnings per share over the last twelve months were -3.16 USD, down 149.0% on the twelve months before. In fiscal year 2025 they were 6.78 USD, up 1,684.2% on the year before.

Last updated 9 Nov 2026 · Next report 9 Feb 2027

EPS

Growth

Fiscal yearPeriod endingEPSGrowthEPS (basic)
TTM30 Sept 2026-3.16-148.99%-3.10
FY202531 Dec 20256.78+1,684.21%6.84
FY202431 Dec 20240.38-91.56%0.38
FY202331 Dec 20234.50+23.63%4.54
FY202231 Dec 20223.64-26.17%3.66
FY202131 Dec 20214.93+4,961.60%4.96
FY202031 Dec 20200.10-97.69%0.10
FY201931 Dec 20194.22+1.20%4.24
FY201831 Dec 20184.17+18.80%4.20
FY201731 Dec 20173.51-64.69%3.54
FY201631 Dec 20169.94-16.54%10.08
FY201531 Dec 201511.91+62.04%12.37
FY201431 Dec 20147.35+306.08%7.95
FY201331 Dec 20131.81+10.37%2.01
FY201231 Dec 20121.64-7.87%1.71
FY201131 Dec 20111.78+7.23%1.81
FY201031 Dec 20101.66+17.73%1.70
FY200931 Dec 20091.41+34.29%1.46
FY200831 Dec 20081.05+25.00%1.09
FY200731 Dec 20070.84—0.87
FY200631 Dec 2006-0.65-251.16%-0.65
FY200531 Dec 20050.43+72.00%0.45
FY200431 Dec 20040.25—0.26
FY200331 Dec 2003-0.04-202.28%-0.04
FY200231 Dec 20020.04+34.77%0.05
FY200131 Dec 20010.03—0.04
FY200031 Dec 2000-0.04—-0.04
FY199931 Dec 1999-0.05—-0.05
FY199831 Dec 1998-0.04—-0.04
FY199731 Dec 1997-0.03—-0.03
FY199631 Dec 1996-0.02—-0.02
FY199531 Dec 1995-0.04—-0.04
FY199431 Dec 1994-0.04—-0.04
FY199231 Dec 1992-0.03—-0.03
FY199131 Dec 1991-0.01—-0.01
FY199031 Dec 1990-0.01—-0.01

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Gilead Sciences's EPS

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.